| Literature DB >> 33020734 |
Miguel Ángel Molina Gutiérrez1, José Antonio Ruiz Domínguez1, Marta Bueno Barriocanal1, Begoña de Miguel Lavisier1, Rosario López López1, Julia Martín Sánchez1, María de Ceano-Vivas la Calle1.
Abstract
INTRODUCTION: SARS-CoV-2, coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in Spain on 31 January 2020. On 14 March 2020, a state of emergency was declared in Spain in a bid to control the spread of the COVID-19 pandemic in the country. The aim of our study is to analyze the impact on emergency medicine attendance after the national lockdown, as well as the clinical presentation and the management of patients with suspected COVID-19 in the Paediatric Emergency Department. PATIENTS AND METHODS: This retrospective observational study included children and adolescents under the age of 18, attended in our Paediatric Emergency Department during the period March 14 to April 17, 2020.Entities:
Keywords: COVID-19; Paediatric emergency medicine; Pandemics
Year: 2020 PMID: 33020734 PMCID: PMC7526690 DOI: 10.1016/j.anpede.2020.06.002
Source DB: PubMed Journal: An Pediatr (Engl Ed) ISSN: 2341-2879
General characteristics (n = 1666).
| <1 month | 78 (4.6%) |
| 1–3 months | 136 (8.1%) |
| 3–6 months | 86 (5.1%) |
| 6–12 months | 96 (5.7%) |
| 1–3 years | 344 (20.6%) |
| 3–5 years | 249 (14.9%) |
| 5–12 years | 443 (26.5%) |
| 12–16 | 186 (11.1%) |
| >16 years | 48 (2.8%) |
| Morning (8:00 a.m.–15:00 p.m.) | 588 (35.2%) |
| Afternoon (15:00 p.m.–21:00 p.m.) | 667 (40%) |
| Night (21:00 p.m.–8:00 a.m.) | 411 (24.6%) |
| Male | 854 (51.2%) |
| Female | 812 (48.7%) |
| I | 1 (0.0%) |
| II | 52 (3.1%) |
| III | 612 (36.7%) |
| IV | 953 (57.2%) |
| V | 48 (2.8%) |
Reason for emergency visit (March 14–April 17).
| 2019 | 2020 | ||
|---|---|---|---|
| Fever | 1027 (21.3%) | 441 (26.5%) | <.001 |
| Respiratory symptoms | 820 (17%) | 269 (16.1%) | .450 |
| Traumatic injury (including burns/animal bites) | 595 (12.3%) | 253 (15.2%) | <.005 |
| Pain | 706 (14.6%) | 227 (13.6%) | .275 |
| Gastrointestinal symptoms (excluding abdominal pain) | 590 (12.2%) | 81 (4.9%) | <.001 |
| Rash/skin lesions (without fever) | 303 (6.2%) | 56 (3.4%) | <.001 |
| Neurologic symptoms (excluding headache) | 93 (1.9%) | 52 (3.1%) | <.005 |
| Bulge/local swelling | 91 (1.8%) | 40 (2.4%) | .225 |
| Behavioural changes | 124 (2.5%) | 33 (2.0%) | .175 |
| Jaundice | 34 (0.7%) | 33 (2.0%) | <.001 |
| Foreign body (any location) | 38 (0.7%) | 28 (1.7%) | <.002 |
| ENT (excluding cold and ENT pain) | 62 (1.2%) | 16 (1.0%) | .275 |
| Suspected COVID | 0 (0%) | 14 (0.8%) | |
| Apnoea/choking/arrest/CPR/drowning | 14 (0.2%) | 9 (0.5%) | .125 |
| Devices (problems) | 18 (0.3%) | 9 (0.5%) | .375 |
| Malaise/asthenia/fatigue | 10 (0.2%) | 9 (0.5%) | <.005 |
| Nephrology (excluding dysuria) | 45 (0.9%) | 8 (0.5%) | .075 |
| Allergic reaction | 22 (0.4%) | 7 (0.4%) | .825 |
| Eye/vision problems | 71 (1.4%) | 6 (0.4%) | <.001 |
| Poisoning/substance exposure (accidental) | 21 (0.4%) | 5 (0.3%) | .425 |
| Infection (miscellaneous) | 22 (0.4%) | 4 (0.2%) | .225 |
| Other | 107 (2.2%) | 66 (4.0%) | <.001 |
| Total | 4813 | 1666 | |
Discharge diagnoses: infectious disease (n = 807/1666).
| 436/807 (54%) | |
| Upper | 264/436 (60.5%) |
| Lower | 172/436 (39.4%) |
| 165/807 (20.4%) | |
| Without a source | 158/165 (95.7%) |
| Occult bacteraemia/sepsis | 7/165 (4.2%) |
| 62/807 (7.6%) | |
| Acute otitis media | 24/62 (38.7%) |
| Viral pharyngotonsillitis | 25/62 (40.3%) |
| Streptococcal pharyngotonsillitis | 4/62 (6.4%) |
| Mastoiditis | 2/62 (3.2%) |
| Other | 7/62 (11.2%) |
| 52/807 (6.4%) | |
| Adenitis | 16/52 (30.7%) |
| Nonspecific viral exanthema | 13/52 (25%) |
| Cellulitis | 5/52 (9.6%) |
| Abscess | 7/52 (13.4%) |
| Skin lesions compatible with COVID-19 | 9/52 (17.3%) |
| Other | 2/52 (3.8%) |
| 30/807 (3.7%) | |
| Afebrile | 16/30 (53.3%) |
| Febrile | 14/30 (46.6%) |
| 28/807 (3.4%) | |
| Acute gastroenteritis | 28/28 (100%) |
| 7/807 (0.8%) | |
| Balanitis | 3/7 (42.8%) |
| Vulvovaginitis | 4/7 (57.1%) |
| 27/807 (3.3%) | |
| Mononucleosis | 6/27 (22.2%) |
| Kawasaki disease | 1/27 (3.7%) |
| Meningitis | 2/27 (22.2%) |
| COVID-19 screening | 13/27 (48.1%) |
| Other | 5/27 (18.5%) |
Discharge diagnoses: surgical conditions and trauma (n = 329/1666).
| 205/329 (62.3%) | |
| | 105/205 (51.2%) |
| | 28/205 (13.6%) |
| | 27/205 (13.1%) |
| | 12/205 (5.8%) |
| | 6/205 (2.9%) |
| | 4/205 (1.9%) |
| | 23/205 (11.2%) |
| 124/329 (37.6%) | |
| | 54/124 (43.5%) |
| Upper extremities | 38/54 (70.3%) |
| Lower extremities | 13/54 (24%) |
| Polytrauma | 3/54 (5.5%) |
| | 30/124 (24.1%) |
| Upper extremities | 21/30 (70%) |
| Lower extremities | 9/30 (30%) |
| | 26/124 (20.9%) |
| With skull fracture | 5/26 (19.2%) |
| | 7/124 (5.6%) |
| Thoracic | 2/7 (28.5%) |
| Lumbar | 1/7 (14.2%) |
| Facial | 4/7 (57.1%) |
Discharge diagnoses other than infectious disease (n = 530/1666).
| 135/530 (25.4%) | |
| Abdominal pain without alarming signs | 55/135 (40.7%) |
| Nonspecific vomiting | 29/135 (21.4%) |
| Gastro-oesophageal reflux | 14/135 (10.3%) |
| Gastrointestinal haemorrhage | 11/135 (8.1%) |
| Constipation | 9/135 (6.6%) |
| Suspected cow's milk protein allergy | 7/135 (5.1%) |
| Other | 10/135 (7.4%) |
| 55/530 (10.3%) | |
| Acute bronchospasm | 54/55 (98.1%) |
| Spontaneous pneumomediastinum | 1/55 (1.8%) |
| 46/530 (8.6%) | |
| Afebrile seizures | 23/46 (50%) |
| Headache with no alarming signs | 7/46 (15.2%) |
| Febrile seizures | 5/46 (10.8%) |
| Shunt malfunction | 4/46 (8.6%) |
| Other | 7/46 (15.2%) |
| 27/530 (5%) | |
| 21/530 (3.9%) | |
| Foreign body in nose/ear | 11/21 (52.3%) |
| Otorrhagia/ear trauma | 2/21 (9.5%) |
| Epistaxis | 4/21 (19%) |
| Other | 4/21 (19%) |
| 16/530 (3%) | |
| Syncope | 8/16 (50%) |
| Arrythmia | 4/16 (25%) |
| Heart failure | 2/16 (12.5%) |
| Other | 2/16 (12.5%) |
| 16/530 (3%) | |
| 14/530 (2.6%) | |
| Nontraumatic limping | 7/14 (50%) |
| Schönlein-Henoch purpura | 2/14 (14.2%) |
| Other | 5/14 (35.7%) |
| 12/530 (2.2%) | |
| 9/530 (1.6%) | |
| 8/530 (1.5%) | |
| 6/530 (1.1%) | |
| 4/530 (0.7%) | |
| Onset of diabetes | 3/4 (75%) |
| Metabolic decompensation in diabetic patient | 1/4 (25%) |
| 3/530 (0.5%) | |
| 158/530 (29.8%) | |
| Non-emergency medical situation | 46/158 (29.1%) |
| Neonatal hyperbilirubinemia | 31/158 (19.6%) |
| Non-traumatic chest pain | 12/158 (7.5%) |
| Allergy/anaphylaxis | 12/158 (7.5%) |
| Poisoning | 5/158 (3.1%) |
| Other | 52/158 (32.9%) |
Figure 1Daily number of new cases of COVID-19 (suspected and confirmed by PRC) diagnosed at the paediatric emergency department and correlation to the reported daily confirmed cases in the Autonomous Community of Madrid (ACM) in the first 35 days following the declaration of the state of alarm. Source of data for the ACM: Spanish Ministry of Health, Social Welfare and Equality.
Figure 2Cumulative frequency of new COVID-19 cases (suspected and confirmed by PCR) diagnosed at the paediatric emergency department and correlation to the reported cumulative number of confirmed cases in the Autonomous Community of Madrid (ACM) in the first 35 days following the declaration of the state of alarm. Source of data for the ACM: Spanish Ministry of Health, Social Welfare and Equality.
Figure 3Flow chart of patients with a discharge diagnosis of infectious disease and of suspected/confirmed COVID-19.
Description of cases diagnosed as possible COVID-19 (n = 218).
| Total, | PCR+, | |
|---|---|---|
| | 96/218 (44%) | 14/96 (14.5%) |
| Pneumonia | 45/96 (46.8%) | 9/45 (20%) |
| Other | 51/96 (53.1%) | 5/51 (9.8%) |
| | 74/218 (33.9%) | 18/74 (24.3%) |
| | 25/218 (11.5%) | 7/25 (28%) |
| | 9/218 (4.1%) | 0/9 (0%) |
| | 1/218 (0.5%) | 0/1 (0%) |
| | 13/218 (6%) | 1/13 (7.6%) |
| | 30/52 (57.6%) | 4/30 (13.3%) |
| Pneumonia | 17/30 (56.6%) | 4/17 (23.5%) |
| | 10/52 (19.2%) | 5/10 (50%) |
| | 10/52 (19.2%) | 6/10 (60%) |
| | 1/52 (1.9%) | 0/1 (0%) |
| | 1/52 (1.9%) | 0/1 (0%) |